ProQR Therapeutics (PRQR) Current Deferred Revenue (2021 - 2024)
Historic Current Deferred Revenue for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $23.4 million.
- ProQR Therapeutics' Current Deferred Revenue rose 594.69% to $23.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.4 million, marking a year-over-year increase of 594.69%. This contributed to the annual value of $23.7 million for FY2024, which is 673.63% up from last year.
- ProQR Therapeutics' Current Deferred Revenue amounted to $23.4 million in Q4 2024, which was up 594.69% from $22.1 million recorded in Q4 2023.
- ProQR Therapeutics' Current Deferred Revenue's 5-year high stood at $69.6 million during Q1 2023, with a 5-year trough of $687.55 in Q1 2021.
- For the 4-year period, ProQR Therapeutics' Current Deferred Revenue averaged around $23.8 million, with its median value being $15.2 million (2022).
- Examining YoY changes over the last 5 years, ProQR Therapeutics' Current Deferred Revenue showed a top increase of 221191323.98% in 2022 and a maximum decrease of 5182.87% in 2022.
- Over the past 4 years, ProQR Therapeutics' Current Deferred Revenue (Quarter) stood at $5.9 million in 2021, then decreased by 1.64% to $5.8 million in 2022, then skyrocketed by 284.54% to $22.1 million in 2023, then rose by 5.95% to $23.4 million in 2024.
- Its Current Deferred Revenue stands at $23.4 million for Q4 2024, versus $22.1 million for Q4 2023 and $56.2 million for Q3 2023.